Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30044070 | 1.00 | MAOB (0.46) | MAOBMAOAALOX15HPGDCES2 | |
| Ammonia Solution, Strong SCHEMBL20295047 | 0.98 | MAOB (0.44) | MAOBMAOAALOX15HPGDCES2 | |
| SCHEMBL30689811 | 0.82 | ALOX15 (0.50) | MAOBMAOAALOX15HPGDCES2 | |
| SCHEMBL247900 | 0.82 | ALOX15 (0.50) | MAOBMAOAALOX15HPGDCES2 | |
| SCHEMBL30475151 | 0.78 | MAOB (0.61) | MAOBMAOAALDH1A1KDM4EMCL1 | |
| SCHEMBL1395661 | 0.78 | MAOB (0.61) | MAOBMAOAALDH1A1KDM4EMCL1 | |
| SCHEMBL22122429 | 0.78 | CHEK1 (0.43) | MAOBMAOAALOX15HPGDCES2 | |
| SCHEMBL1267080 | 0.76 | ESR2 (0.44) | CES2ESR1ESR2UPP1 | |
| SCHEMBL1343170 | 0.76 | MAOB (0.48) | MAOBMAOAALOX15ALDH1A1LMNA | |
| SCHEMBL17937888 | 0.75 | PGR (0.48) | MAOBMAOAALOX15HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2026-05-28 | — | — | US | disclosed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026098672-A1 | BIAZACYCLOALKANE MENIN-MLL PROTEIN INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4729515-A1 | NEW ACYLSULFONAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-04-22 | — | — | EP | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260035360-A1 | INHIBITORS OF MYC AND USES THEREOF | UNIV NORTHWESTERN (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | NURIX THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20050139814-A1 | Benzofuran and benzothiophene derivatives useful in the treatmint of hyper-proliferative disorders | BAYER HEALTHCARE LLC | 2005-06-30 | — | — | US | disclosed |
| EP-1383511-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-05-18 | — | — | EP | disclosed |
| WO-2005014566-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
| EP-1487813-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1383511-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040014723-A1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION | 2004-01-22 | — | — | US | disclosed |
| WO-2003072561-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
| US-6417215-B1 | USE AS CALCIUM RECEPTOR ANTAGONISTS. EXTRACELLULAR CA.SUP.2+ INHIBITS THE SECRETION OF PARATHYROID HORMONE (?PTH?) FROM PARATHYROID CELLS, | SMITHKLINE BEECHAM CORPORATION | 2002-07-09 | — | — | US | disclosed |
| WO-2002034204-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-02 | — | — | WO | disclosed |
| CN-1346269-A | Calcilytic compounds | SMITHKLINE BEECHAM CORP (US) | 2002-04-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | RYR2, CACNA1C, CAMK4 | MAOB 1358/4885MAOA 1555/4885ALOX15 2007/4885 |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | IRAK1, IRAK2, IRAK3 | MAOB 4180/4885MAOA 4285/4885ALOX15 4099/4885 |
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | PTPN6, PTPN1, PTPN11 | MAOB 4840/4885MAOA 4800/4885ALOX15 3864/4885 |
| US-20040014723-A1 | Calcilytic compounds | SOST, CALCB, CALCR | MAOB 3994/4885MAOA 4637/4885ALOX15 2806/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | MAOB 3498/4885MAOA 3293/4885ALOX15 4882/4885 |
| US-20260035360-A1 | INHIBITORS OF MYC AND USES THEREOF | MYC, MYCBP, MYCBP2 | MAOB 4214/4885MAOA 4169/4885ALOX15 3338/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | MAOB 3338/4885MAOA 2679/4885ALOX15 4768/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | MAOB 2815/4885MAOA 2201/4885ALOX15 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.